20 Assessment of Textbook Oncologic Outcomes Following Modified Radical Mastectomy for Invasive Ductal Carcinoma: A Review of the 2004-2017 National Cancer Database

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement38th Annual Miami Breast Cancer Conference® - Abstracts
Volume 35
Issue suppl 1
Pages: 32-33

Gabriela L. Aitken, MD1; Gabriel Correa, MD1; Shenae Samuels, PhD, MPH1; Christopher J. Gannon, MD1; Omar H. Llaguna, MD1

1Memorial Healthcare System, Hollywood, FL

Background

Textbook oncologic outcome (TOO) is a composite outcome measure attained when all desired shortterm quality metrics are met, following an oncologic operation. The objective of this study was to determine the incidence of TOO and its impact on overall survival (OS) among patients with a diagnosis of invasive ductal carcinoma (IDC) following modified radical mastectomy (MRM).

Design and Methods

The 2004 to 2017 National Cancer Database was queried for patients with nonmetastatic IDC who underwent MRM. The TOO was defined as having attained 5 metrics: resection with negative microscopic margins; American Joint Committee on Cancer compliant lymph node evaluation (n 10); no prolonged length of stay (50th percentile by year); no 30-day readmission; and no 30-day mortality. Categorical variables were analyzed using Pearson’s 2 test or Fisher’s exact test where appropriate. Continuous variables were analyzed using independent t-tests. The OS was defined as the time in months between the date of diagnosis and date of death or last contact. The Kaplan-Meier method with log-rank test was used to compare and estimate OS rates between patients with TOO and patients without TOO (non-TOO).

Results

A total of 75,063 patients were identified, of which 40.8% achieved TOO. The patients with TOO had a lower median age and were more likely to be White, privately insured, and without comorbidities. In terms of facility characteristics, patients with TOO were more likely to be seen in comprehensive community cancer programs with a high case volume per year. Patients with T2, N1, pathologic stage 2, poorly differentiated pathology, and estrogen receptor–positive, progesterone receptor–positive, HER2-negative hormone receptor status were also more likely to have achieved TOO. The TOO group had a higher lymph node yield (TOO, 17.0 ± 6.2 vs non-TOO, 10.6 ± 7.3; P = .000) and higher average number of positive lymph nodes (TOO, 4.1 ± 5.4 vs non-TOO, 2.7 ± 4.5; P = .000). The TOO group had a statistically significant higher median OS compared with the non-TOO group (165.6 vs 142.2 months; P = .000).

Conclusions

The TOO was achieved in approximately 41% of patients undergoing MRM for IDC. Achieving TOO is associated with improved median OS, and therefore, merits further attention in efforts to improve surgical outcomes.

Articles in this issue

1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
45 Neoadjuvant Chemotherapy Use in Elderly Patients
45 Neoadjuvant Chemotherapy Use in Elderly Patients
Related Content